共 268 条
[1]
Cardoso F(2014)ESO-ESMO 2th International consensus guidelines for advanced breast cancer (ABC2) Ann Oncol 25 1871-1888
[2]
Costa A(2001)Anastrozole is superior to tamoxifen as first line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2247-2258
[3]
Norton L(2003)Anastrozole (Arimidex) versus tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results Eur J Cancer 39 1684-1689
[4]
Senkus E(2003)Phase III study of letrozole versus tamoxifen as first line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group J Clin Oncol 21 2101-2109
[5]
Aapro M(2007)Phase III study comparing exemestane with tamoxifen as first line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organization for research and treatment of Cancer Breast Cancer Cooperative Group J Clin Oncol 26 4883-4890
[6]
Andrè F(2008)Double blind randomized placebo controlled trial of fulvestrant compared with exemestane after prior non steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor positive advanced breast cancer: results from EFECT J Clin Oncol 26 1664-1670
[7]
Boneterre J(2010)Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor positive advanced breast cancer J Clin Oncol 28 4594-4600
[8]
Buzdar A(2014)Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial J Natl Cancer Inst 106 1-7
[9]
Nabholtz JM(2014)Phase III study of letrozole versus tamoxifen as first line therapy of advanced breast cancer in postmenopausal women: analysis of survival and updated of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 22 3199-3200
[10]
Robertson JF(2011)Hallmarks of cancer: the next generation Cell 144 646-674